May 14th 2024
In a comparison of pediatric dermatologists versus AI, dermatologists primarily exhibited greater performance.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Giving Bureaucracy the Ol' College Try
July 1st 2003Having recently returned to my "roots" to assume the position of professor and chief of dermatology at my alma mater, the University of Arizona, I'm struck by the fact that, although many changes have occurred during the 30 years I've been away pursuing other academic positions and activities, much remains the same. Predictably, the campus has grown and
Bucking the One-Time Trendsetter
June 1st 2003San Francisco - According to an analysis of data from more than 700 patients, a new nonsteroid treatment for atopic dermatitis is a safe, effective, and cost-effective alternative to conventional therapy for the chronic, relapsing inflammatory skin disease that primarily affects infants and children.
TIM's: Trying to Draw Comparisons
June 1st 2003San Francisco -- Results of a study evaluating topical tacrolimus ointment 0.03 percent (Protopic) indicate it is a safe and effective treatment for patients of all ages with mild to moderate atopic dermatitis (AD), John Y M Koo, M.D., said at the annual meeting of the American Academy of Dermatology.